Abstract 5619
Background
Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1 (HSV-1), which can be administered intralesionally in patients with stage IIIB/C-IVM1a unresectable melanoma. When surgery is not a treatment option in the head and neck region, i.e. due to the location or the size of the tumor, T-VEC therapy can be an elegant alternative to systemic immunotherapy.
Methods
9 patients with melanoma in the head and neck region started treatment with T-VEC monotherapy at the Netherlands Cancer Institute, of which 4 are still currently on treatment. We collected data on response, adverse events (AE) and baseline characteristics. For response evaluation, we used clinical evaluation with photography, 3-monthly PET-CT’s and histological biopsies.
Results
Median age at baseline was 78.3 years. Of the 5 patients who stopped treatment, the median follow-up time was 9.1 months. Of these patients, 3 (60%) had a complete response (CR), 1 (20%) patient had a partial response (PR) and 1 (20%) patient showed progressive disease (PD) as their best response. ORR was 80%. Duration of response varies between 1.6-21.6 months. 2 patients developed distant metastases, 1 during T-VEC treatment and 1 after achieving a CR with a time to progression of 14.2 months. 4 patients are still on treatment today. Grade 1 AE’s occurred in all patients. Mostly, these consisted of fatigue, influenza-like symptoms and injection site pain. PET-CT and histological biopsies proved to be a clinically useful tool to evaluate treatment response for T-VEC monotherapy, confirming pCR or PD to stage IV disease requiring systemic treatment.
Conclusions
ORR for T-VEC monotherapy for melanoma in the head and neck region at our institute was 80% with 60% achieving a CR. This real world data on T-VEC monotherapy in stage IIIB/C-IVM1a unresectable melanoma of the head and neck region demonstrates interesting results and suggests T-VEC is an elegant alternative to systemic therapy in this select elderly and frail patient population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Franke: Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): amgen. M.W.J.M. Wouters: Research grant / Funding (institution): Novartis. W.J. van Houdt: Advisory / Consultancy, Research grant / Funding (institution): amgen. A.C.J. van Akkooi: Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): amgen; Research grant / Funding (institution): BMS; Research grant / Funding (institution): MSD-Merck; Research grant / Funding (institution): Merck-Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
3664 - Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract